Related Experiment Video
Updated: May 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Expanding the indication spectrum: renal denervation in diabetes
Felix Mahfoud1, Sebastian Ewen, Christian Ukena
1Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. felix.mahfoud@uks.eu
Abstract:
Catheter-based renal denervation (RDN) has been shown to reduce sympathetic nerve activity and blood pressure in patients with resistant hypertension. Increased central sympathetic activity is a main contributor to the pathophysiology of several important chronic cardiovascular diseases, including diabetes and the metabolic syndrome. Indeed several recently published pilot studies and case reports suggest beneficial effects of RDN on glucose metabolism in patients with resistant hypertension. This review highlights the background of approaching the renal sympathetic nerves as a potential new therapeutic option to improve glycaemic control in patients with resistant hypertension.
Related Concept Videos
Diabetic Nephropathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Diabetic Retinopathy
Diabetic Neuropathy
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management
